Successful withdrawal of antiviral treatment in two HBV-related liver
transplant recipients after hepatitis B vaccination with long-term
follow-up
Man Xie a , Yun-Jin Zang b , c , Bei Zhang d , Wei Rao b , c , ∗
a Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao 266600, China
b Division of Hepatology, Liver Disease Center, the Affiliated Hospital of Qingdao University, Qingdao 266600, China
c Department of Organ Transplantation, the Affiliated Hospital of Qingdao University, Qingdao 266600, China
d Department of Immunology, Medical College of Qingdao University, Qingdao 266071, China
Abstract：Hepatitis B immunoglobulin (HBIG) combined with nucleos( t)ide analogues (NAs) has become the standard regimen for preventing recurrence of hepatitis B virus (HBV) infection in HBV-related liver transplant (LT) recipients. HBsAg seropositivity was detected in only 7.2%–8.6% of LT recipients who received monotherapy with high-genetic-barrier NAs after a short period of combined therapy [1,2]. Despite progress in the application of newer NAs in HBV-related LT recipients, complete withdrawal of HBV prophylaxis after LT was controversial and considered risky by some centers [3]. We here present two cases of complete and sustained HBV cccDNA-negative status after withdrawal of prophylaxis when intrahepatic and active immune response was achieved with hepatitis B vaccination. Our experience provides a strategy for reliable and safe withdrawal of anti-HBV prophylaxis in HBV-related LT recipients.
引用本文:
. [J]. Hepatobiliary Pancreat Dis Int, 2021, 20(6): 595-597.
Xie M, Zang YJ, Zhang B, Rao W. Successful withdrawal of antiviral treatment in two HBV-related liver
transplant recipients after hepatitis B vaccination with long-term
follow-up. Hepatobiliary Pancreat Dis Int, 2021, 20(6): 595-597.
2021, Vol. 20 
